Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma

Leon D. Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy Abramson, Jacob Soumerai, Maria Martinez-Lage, Julie Haydu, Ganesh Shankar, Chirayu Patel, Bryan D. Choi, Jeffrey Barnes, Areej El-Jawahri, Ephraim Hochberg, Patrick Connor Johnson, Wolfgang Wick, Marcela Maus, Yi-Bin Chen, Matthew Frigault, Jorg Dietrich

Blood (2025) 146 (Supplement 1): 5493.

https://doi.org/10.1182/blood-2025-5493

Published: 2025

Journal Articles

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Blood (2025) 146 (Supplement 1): 2392.

https://doi.org/10.1182/blood-2025-2392

Published: 2025

Journal Articles

Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.

Joshua Gustine, Narsis Attar, Benjamin Puliafito, Diana Cirstea, Andrew Branagan, Marcela Maus, Matthew Frigault, Andrew Yee, Noopur Raje

Blood (2025) 146 (Supplement 1): 2243.

https://doi.org/10.1182/blood-2025-2243

Published: 2025

Journal Articles

First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance

Blood (2025) 146 (Supplement 1): 270.

https://doi.org/10.1182/blood-2025-270

Published: 2025

Journal Articles

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Narsis Attar, Rajib Shome, Mehmet Samur, Joshua Gustine, Charlotte Graham, Kathleen ME Gallagher, Agustin Busse, Deshea L Harris, Diana Cirstea, Andrew Yee, Andrew Branagan, Marcela Maus, Matthew Frigault, Nikhil Munshi, Adam Sperling, Noopur Raje

Blood (2025) 146 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2025-5764

Published: 2025

Journal Articles

Triple base-edited dual targeting CD70/33 CAR T cells to avoid cytokine-mediated resistance in Acute Myeloid Leukemia

Alexandra Bratt, Grace Martin, Merle Phillips, Sophia Nigrovic, Filippo Birocchi, Cassiddy Ho, Andrew Hwang, Adele Mucci, Nicholas Haradhvala, Magdi Elsallab, Marcela Maus, Mark Leick

Blood (2025) 146 (Supplement 1): 5879.

https://doi.org/10.1182/blood-2025-5879

Published: 2025

Journal Articles

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

Blood (2025) 146 (Supplement 1): 503.

https://doi.org/10.1182/blood-2025-503

Published: 2025

Journal Articles

Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.

Joshua Gustine, Narsis Attar, Benjamin Puliafito, Diana Cirstea, Andrew Branagan, Marcela Maus, Matthew Frigault, Andrew Yee, Noopur Raje

Blood (2025) 146 (Supplement 1): 5792.

https://doi.org/10.1182/blood-2025-5792

Published: 2025

Journal Articles

Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Joshua Gustine, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Marcela Maus, Matthew J. Frigault, Noopur Raje

Blood (2024) 144 (Supplement 1): 79.

https://doi.org/10.1182/blood-2024-212135

Published: 2024

Journal Articles

Generation of Functional iPSC-Derived CAR-T Cells for Cancer Immunotherapy Via G9a/GLP Inhibition

Ran Jing, Marcelo Falchetti, Tianxiao Han, Mohamad Najia, Luca Hensch, Eleanor Meader, Martin Kononov, Stephanie Wang, Caroline Kubaczka, Edroaldo Lummertz Da Rocha, Robert Grant Rowe, Thorsten M. Schlaeger, Marcela Maus, Trista E. North, Leonard I. Zon, George Q. Daley

Blood (2024) 144 (Supplement 1): 2043.

https://doi.org/10.1182/blood-2024-208634

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.

First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Triple base-edited dual targeting CD70/33 CAR T cells to avoid cytokine-mediated resistance in Acute Myeloid Leukemia

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.

Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Generation of Functional iPSC-Derived CAR-T Cells for Cancer Immunotherapy Via G9a/GLP Inhibition

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only